glp 1 agonist companies Oral Non-Peptide GLP-1 Receptor Agonists Market Key Players The Growing Market for

glp 1 agonist companies Oral Non-Peptide GLP-1 Receptor Agonists Market Key Players The Growing Market for

The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists

Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease

2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)